What is Lake Street Capital’s Forecast for CLPT Q3 Earnings?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Equities researchers at Lake Street Capital issued their Q3 2026 earnings per share estimates for shares of ClearPoint Neuro in a research note issued to investors on Tuesday, October 20th. Lake Street Capital analyst F. Takkinen forecasts that the company will post earnings per share of ($0.36) for the quarter. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($1.22) per share.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Thursday, October 15th. Stifel Nicolaus set a $22.00 target price on shares of ClearPoint Neuro in a report on Tuesday, August 4th. Finally, Wall Street Zen downgraded ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, ClearPoint Neuro currently has an average rating of “Hold” and a consensus price target of $25.67.

ClearPoint Neuro Stock Performance

Shares of CLPT stock opened at $9.25 on Thursday. The company has a market cap of $282.12 million, a P/E ratio of -7.84 and a beta of 1.29. ClearPoint Neuro has a one year low of $8.27 and a one year high of $27.27. The company has a debt-to-equity ratio of 4.66, a current ratio of 4.74 and a quick ratio of 3.89. The firm has a 50-day moving average of $13.26 and a 200-day moving average of $13.51.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.09). The business had revenue of $10.88 million for the quarter, compared to analyst estimates of $12.73 million. ClearPoint Neuro had a negative return on equity of 188.09% and a negative net margin of 81.76%. During the same quarter last year, the firm posted ($0.21) EPS.

Hedge Funds Weigh In On ClearPoint Neuro

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in ClearPoint Neuro in the 2nd quarter worth $42,456,000. SG Americas Securities LLC purchased a new stake in ClearPoint Neuro during the first quarter valued at $3,388,000. Compass Financial Management LLC bought a new position in ClearPoint Neuro during the second quarter valued at $5,275,000. Bank of New York Mellon Corp bought a new position in ClearPoint Neuro during the second quarter valued at $2,708,000. Finally, FirstWave Capital Management LLC grew its stake in shares of ClearPoint Neuro by 20.6% in the 2nd quarter. FirstWave Capital Management LLC now owns 115,600 shares of the company’s stock worth $2,062,000 after buying an additional 19,760 shares in the last quarter. 30.08% of the stock is owned by institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes image-guided systems for minimally invasive neurosurgical procedures. Its platform is designed to help physicians plan, navigate and monitor procedures within the brain, using magnetic resonance imaging (MRI) to support accurate placement of instruments and therapeutic agents.

The company’s product portfolio includes the ClearPoint Neuro navigation system and related disposable components, including cranial access and guidance products.